HMGCR and prostate carcinoma: Additionally, a set of 424 SNPs used as a genetic instrument for circulating LDL-c was weakly associated with prostate cancer risk (OR = 0.95, 95% CI = 0.88 to 1.01, P = 0.096) with similar effect estimates to those found for HMGCR inhibition (heterogeneity P = 0.432).